The global acetylcholine demand is projected to be valued at US$ 2. 5 billion in 2022, forecast to grow at a CAGR of 4.3% to be valued at US$ 4 Billion from 2022 to 2032. Growth is attributed to the rising demand for renovation projects and development in residential and commercial construction.
| Report Attribute | Details |
| Estimated Base Year Value (2021) | US$ 2.2 Billion |
| Expected Market Value (2022) | US$ 2.5 Billion |
| Anticipated Forecast Value (2032) | US$ 4 Billion |
| Projected Growth Rate (2022-2032) | 4.3 % CAGR |
Acetylcholine (Ach) is a chemical compound derived from choline and acetic acid. It is a prescription drug used in the preparation of a parasympathomimetic drug for intraocular usage. Acetylcholine plays a vital role in the central nervous system as a neurotransmitter. It is used by organisms in all domains of life. Acetylcholine has two key receptors- nicotinic receptors and muscarinic receptors.
Acetylcholine acts at various sites within the central nervous system where it plays an inhibitory role. Moreover, acetylcholine act as a key force in the functions of the brain, such as working memory, linguistic skills, and ability to reason and use logic, creativity. Also, acetylcholine is utilized to activate our muscle’s involuntary movement, mobility, and coordination, other applications.
Demographic changes, globalization, and growth in population have contributed to the healthcare services and increased the demand of the pharmaceutical industry. Further, increased awareness of health among citizens, especially in developing countries, is boosting the government health programs which ultimately drive the growth of the global acetylcholine market by end of the forecast period. The premium-priced life-saving drugs can act as leverage for the market development of ingredients including acetylcholine.
OTC (over-the-counter) drugs are medicines that can be bought without a prescription from the doctor as the FDA (Food and Drug Administration) considers them safe for use without medical supervision. These drugs have a solution to numerous problems, such as cough & cold, pain, sleeping problems, itches, weight problems, smoking cessation, and gastrointestinal problems. Brain functions that have been negatively affected by OTC (over-the-counter) medicines aren’t permanent. The brain will recover once neurotransmitter release (like acetylcholine) is helping to back up to the normal level. As a result, demand for acetylcholine is estimated to continuously increase due to its superior properties of acetylcholine.
As per the research, few patients are facing negative effects of acetylcholine-like depression, and the stringent regulations for acetylcholine synthesis in various economies. This is estimated to act as a restraining factor for the global acetylcholine market.
The increasing population in the Asia Pacific region is estimated to gain high demand for acetylcholine in the region. Moreover, South East Asia Pacific region is anticipated to be a significant platform for the global acetylcholine market in the upcoming few years due to rising pharmaceutical production and healthcare services
Moreover, In China, COPD is one of the most prevalent chronic diseases in the population older than 40 years of age, with an occurrence of 8.2% in 2013 and amplified to 13.6% in 2019 using a spirometry-based survey. A relatively higher prevalence with 13.7% to 13.4% was noted in Korea using a spirometry-based survey.
Based on recent market research in the Asia-Pacific region, it was summarized that the prevalence of COPD is between 6.2 to 19.1%
North America is expected to account for a prominent revenue share in the global muscarinic acetylcholine receptor market owing to the high patient pool suffering from COPD and other disorders. In the United States, an estimated 16 million adults have COPD. Nevertheless, that may be an underestimate.
The American Lung Association (ALA) contemplates there may be as many as 24 million American adults living with COPD. Additionally, over 7 million U.S. women have COPD, and millions more are supposed to have symptoms, yet haven’t been analyzed.
Some of the key participants present in the global demand for Acetylcholine market include Tokyo Chemical Industry Co., Ltd, SIEGFRIED LTD, Merck KGaA, NeuroHealing Pharmaceuticals Inc., Karuna Pharmaceuticals Inc., and Sisco Research Laboratories Pvt. Ltd., Heptares Therapeutics Ltd, Toucan, Sumitomo Dainippon Pharma Co Ltd, AstraZeneca Plc, Anavex Life Sciences Corp and among others
| Report Attribute | Details |
| Growth Rate | CAGR of 4.3% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2016-2021 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
Product Form:
Product Type:
Applications:
Region:
FMI projects the global demand of the Acetylcholine market to expand at a 4.3% value CAGR by 2032
North America is expected to be the most opportunistic Acetylcholine market, expanding at a ~4% CAGR
Tokyo Chemical Industry Co., Ltd, SIEGFRIED LTD, Merck KGaA, NeuroHealing Pharmaceuticals Inc., Karuna Pharmaceuticals Inc., and Sisco Research Laboratories Pvt. Ltd., Heptares Therapeutics Ltd, Toucan, Sumitomo Dainippon Pharma Co Ltd, AstraZeneca Plc, Anavex Life Sciences Corp and among others
Acetylcholine Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
